Pre- and post-surgery treatment for HER2+ hepatoid stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment plan given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It's for people whose tumors have a specific HER2 protein marker and are at an early enough stage that surgery is still possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your stomach cancer must be the 'hepatoid adenocarcinoma' type.
- Your tumor must have a positive HER2 result (1+, 2+, or 3+ by IHC).
- Your cancer must be stage II or III (not stage I or IV).
- You need to be healthy enough for daily activities (ECOG score 0 or 1) and able to undergo surgery and the treatment before it.
- You cannot have had any other cancer treatment before joining this trial.
- Your tumor must not have a mismatch repair deficiency or high microsatellite instability.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It aims to improve outcomes for patients whose tumors are HER2-negative and have not spread too far.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
This trial tests a combination of immunotherapy (serplulimab), a targeted HER2 therapy (trastuzumab), and chemotherapy (SOX) after stomach cancer surgery. The goal is to see if this combination reduces the chance of cancer returning in people with HER2-positive stomach cancer.
This trial is looking at whether giving extra treatment after surgery for stomach cancer can help lower the chance of it coming back. It is for people who had a specific kind of chemotherapy and immunotherapy before surgery and then had their stomach removed.
This trial tests two new investigational drugs (SHR-A1811 and SHR-A1701) given before surgery for stomach cancer that is HER2-positive and may respond to immunotherapy. The goal is to see if these drugs can shrink the tumor or improve outcomes when combined with surgery.
Hear when a new Hepatoid Adenocarcinoma of Stomach trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.